Inhibitory Effects of of Tacrine Derivatives on Activity of Prostanoids Biosynthesis Prostaglandin Biosynthesis: A Potential Use for Degenerative Brain Disease Treatment

퇴행성 뇌질환 치료제 Tacrine 유도체의 프로스타글란딘 생합성 억제효과

  • Shin Hea Soon (College of Pharmacy, Duksung Women's University)
  • 신혜순 (덕성여자대학교 약학대학)
  • Published : 2005.02.01

Abstract

Tacrine analogues for degenerative brain disease treatments have been designed. A series of diazaanthrine derivatives as novel analogues of tacrine has been prepared through the alkyl substitution and the ring expansion. They were expected to retain anti-inflammatory activity by inhibition of prostaglandin production with reduction of side effect as the selective prostaglandin synthase inhibitor. Prostaglandin synthase expression is associated with the deposition of beta-amyloid protein in neuritic plaques in brain inflammation. Therefore selective prostaglandin synthase blockade is important for the prevention and treatment of alzheimer's disease. To evaluate inhibitory effect of prostaglandin synthase, synthetic tacrine derivatives were screened with accumulation of prostaglandin biosynthesis by lipopolysaccharide in aspirin-treated murine macrophage cell. Most of synthetic compounds have shown significant prostaglandin synthase activities in vitro screening with $84.3{\sim}33.6\%$ inhibition of the prostaglandin $E_2$ production at $10\;{\mu}g/ml$.

Keywords

References

  1. Korea National Statistical Office. Statistical Yearbook, 2002
  2. Anderson, K., Launer, L. J., Ott, A., Hoes, A. W., Breteler, M. M. and Hofman, A. : Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam Study. Neurology 45, 1441 (1995) https://doi.org/10.1212/WNL.45.8.1441
  3. Combs, C. K., Johnson, D. E., Karlo, J. C., Cannady, S. B. and Landreth, G. E. : Inflammatory mechanism in Alzheimer's disease: inhibition of $\beta$-amyloid-stimulated proinflammatory responses and neurotoxicity by PPAR gamma agonists. J. Neurosci. 20, 558 (2000)
  4. Grundman, M., Corey-Bloom, J. and Thai, L. J. : Perspectives in clinical Alzheimer's disease research and the development of antidementia drugs. J. Neural. Transm. Suppl. 53, 255 (1998)
  5. Oka, A. and Takashima, S. : Introduction of cyclooxygenase 2 in brains of patients with Down's syndrome and dementia of Alzheimer type: specific localization in affected neurones and axons. Neuroreport 8, 1161 (1997) https://doi.org/10.1097/00001756-199703240-00020
  6. Pasinetti, G. M. : Cyclooxygenase and inflammation in Alzheimer's disease: experimental approaches and clinical interventions. J. Neurosci. Res. 54, 1 (1998) https://doi.org/10.1002/(SICI)1097-4547(19981001)54:1<1::AID-JNR1>3.0.CO;2-M
  7. Kish, S. J., Mastrogiacomo, F., Guttman, M., Furukawa, Y., Taanman, J. W., Dozic, S., Pandolfo, M., Lamarche, J., DiStefano, L. and Chang, L. J. : Decreased brain protein levels of cytochrome oxidase subunits in Alzheimer's disease and in hereditary spinocerebellar ataxia disorders: a nonspecific change? J. Neurochem. 72, 700 (1997) https://doi.org/10.1046/j.1471-4159.1999.0720700.x
  8. Montine, T. J., Sidell, K. R., Crews, B. C., Markesbery, W. R., Marnett, L. J., Roberts, L. J. and Morrow, J, D. : Elevated CSF prostaglandin $E_2$ levels in patients with probable AD. Neurology 53, 1495 (1999) https://doi.org/10.1212/WNL.53.7.1495
  9. Kiminobu, S., Tolga, U., Vinod, K. and Hari, M. : New anti-inflammatory treatment strategy in Alzheimer's disease. Jpn. J Pharmacol. 82, 85 (2000) https://doi.org/10.1254/jjp.82.85
  10. Tocco, G., Freire-Moar, J., Schreiber, S. S., Sakhi, S. H., Aisen, P. S. and Pasinetti, G. M. : Maturational regulation and regional induction of cyclooxygenase-2 in rat brain: implications for Alzheimer's disease. Exp. Neurol. 144, 339 (1997) https://doi.org/10.1006/exnr.1997.6429
  11. McGeer, P. L., Schulzer, M. and McGeer, E. G. : Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 47, 425 (1996) https://doi.org/10.1212/WNL.47.2.425
  12. Dray, F., Mamasd, S. and Bizzini, B. : Problems of PGE antisera specificity. Meth. Enzymol. 86, 258 (1982) https://doi.org/10.1016/0076-6879(82)86198-3
  13. hanmugam, P., Feng, L., Liou, S., Jang, B., Boudreau, M., Yu, G., Lee, J., Kwon, H., Beppu, T., Yoshida, M., Xia, Y., Wilson, C. B. and Hwang, D. : Radicinol, a protein tyrosine kinase inhibitor, suppresses the expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysacch-aride and in experimental glomerulo-nephritis. J Biol. Chem. 270, 5418 (1995) https://doi.org/10.1074/jbc.270.10.5418
  14. Lap, H., Cristiana, P., David, W., Dushyant, P. P., Paul, S. A. and Pasinetti, G. M. : Regional distribution of cyclooxygenase-2 in the hippocampal formation Alzheimer's disease. J. Neurosci. Res. 57, 295 (1999) https://doi.org/10.1002/(SICI)1097-4547(19990801)57:3<295::AID-JNR1>3.0.CO;2-0
  15. Herschman, H. R. ; Prostaglandin synthase 2. Biochim. Biophys. Acta 1299, 125 (1996) https://doi.org/10.1016/0005-2760(95)00194-8
  16. McKenna, M. T., Proctor, G. R, Young, L. C. and Harvey, A. L. : Novel tacrine analogues for potential use against Alzheimer's disease: Potent and selective acetylcholinesterase inhibitors and 5-HT uptake inhibitors. J Med. Chem. 40, 3516 (1997) https://doi.org/10.1021/jm970150t
  17. Yasojima, K., Schwab, C., Mcgeer, E. G. and Mcgeer, P. L. : Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs. Brain. Res. 830, 226 (1999) https://doi.org/10.1016/S0006-8993(99)01389-X
  18. Yermakova, A. V., Rollins, J., Callahan, L. M., Rogers, J, and O'Banion. M. K. : Cyclooxygenase-1 in human Alzheimer and control brain: quantitative analysis of expression by microglia and CA3 hippocampal neurons. J. Neurpathol. Exp. Neuol. 58, 1135 (1999) https://doi.org/10.1097/00005072-199911000-00003
  19. O'Banion, M. K., Chang, J. W., Kaplan, M. D., Yermakova, A. and Coleman, P. D. : Glial and neuronal expression of cyclooxygenase-2: relevance to Alzheimer disease. Adv. Exp. Med. Biol. 433, 177 (1997)
  20. Rogers, J., Kirby, L. C., Hempelman, S. R., Berry, D. L., McGeer, P. L., Kaszinak, A. W., Zalinski, J., Cofeld, M., Mansukhani, L., Willson, P. and Korgan, F. : Clinical trial of indometacin in Alzheimer's disease. Neurology 43, 1609 (1993) https://doi.org/10.1212/WNL.43.8.1609
  21. Aisen, J. S. and Davis, K. L. : Inflammatory mechanism in Alzheimer's disease: implications for therpy. Am. J. Psychiat. 151, 1105 (1994) https://doi.org/10.1176/ajp.151.8.1105
  22. Lukiw, W. J. and Bazan, N. G. : Cyclooxygenase 2 RNA message adundance. stability and hypervariability in sporadic Alzheimer neocortex. J. Neurosci. Res. 50, 937 (1997) https://doi.org/10.1002/(SICI)1097-4547(19971215)50:6<937::AID-JNR4>3.0.CO;2-E